MAP BioPharma
Case Study

MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.

Case study 6:

MAP’s work on improving access to orphan medicines has helped to strengthen the case for change and encourage greater external pressure


  •  An increasing number of clients were bringing orphan medicines to market and being referred for a Single Technology Appraisal instead of via the tailored Highly Specialised Technology route. There was limited coordination within the stakeholder community on this topic and a need to refresh the narrative on the case for change.


  •  We established a Steering Group of supporting companies and developed an evidence-based report to make the case for change in rare diseases.

  •  Our media campaign was launched resulting in one significant national news piece and six pharma sector news pieces.

  •  Rolling engagement programme with 8 mentions in the UK Parliament of the report and its findings.

  •  Parliamentary event with attendance of 13 charities and 8 Parliamentarians at Parliamentary roundtable.

  •  Policy updates were provided for supporting companies.


  •  Recognition by NICE of need for flexibilities in STA process and active reference of the need for interim recommendations in the draft NHS Commercial Framework.

  •  Contributing new evidence helped to reset the narrative and provide a clear mandate that the NICE methods review could deliver change.

  •  Greater focus on orphan medicines from groups such as the ABPI.

Case study-diagram
CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52